<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532528</url>
  </required_header>
  <id_info>
    <org_study_id>1160-0304</org_study_id>
    <nct_id>NCT04532528</nct_id>
  </id_info>
  <brief_title>ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years</brief_title>
  <official_title>Relationship of Advanced Holding Education and ADherence on Antithrombotic in Younger SPAF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lifelong oral anticoagulant (OAC) therapy is the preferred treatment for the prevention of&#xD;
      thromboembolic events in the majority of patients with Atrial Fibrillation (AF). Adherence to&#xD;
      medication is essential for valid treatment for OAC therapy.&#xD;
&#xD;
      The study aims to explore whether the advanced educational intervention would improve the&#xD;
      adherence to dabigatran.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with high adherence to dabigatran treatment at month 12 in patients with and without advanced educational intervention</measure>
    <time_frame>up to 12 months</time_frame>
    <description>High adherence is defined as achieving a Morisky 8-Item Medication Adherence Questionnaire (MMAS-8) score of 8 Points.&#xD;
The MMAS-8 is an 8-item structured, self-report measure that assesses medication adherence. If a patient scores higher on the scale, they are evaluated as more adherent. If they score lower on the scale, they are presumed to be struggling with non-adherence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with high adherence to dabigatran treatment at 3, 6, and 9 months in patients with and without advanced educational intervention</measure>
    <time_frame>up to 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with medium (MMAS-8 score: 6 - 7 points) and low (MMAS-8 score &lt; 6 points) adherence to dabigatran treatment at 3, 6, 9, and 12 months in patients with and without advanced educational intervention</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean MMAS-8 score at 3, 6, 9, and 12 months in patients with and without advanced educational intervention</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate of dabigatran in patients with and without advanced educational intervention</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with reasons for discontinuation of dabigatran</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients receiving standard of care (SOC)</arm_group_label>
    <description>(without advanced educational Intervention)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients receiving SOC with advanced educational intervention</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Dabigatran</description>
    <arm_group_label>Patients receiving SOC with advanced educational intervention</arm_group_label>
    <arm_group_label>Patients receiving standard of care (SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients newly diagnosed with AF within 1 month, under 75 years old, and newly&#xD;
        prescribed with dabigatran on physician's decision per local labelling will be equally&#xD;
        randomized to receive standard of care (routine clinical practice) or standard of care&#xD;
        (routine clinical practice) with advanced educational intervention.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients can be included if ALL the following criteria are met:&#xD;
&#xD;
          1. Provide written informed consent prior to participation&#xD;
&#xD;
          2. Female or male adult patients aged â‰¥ 20 years and &lt; 75 years, newly diagnosed with&#xD;
             non-valvular atrial fibrillation (NVAF) within 1 month and has newly prescribed with&#xD;
             dabigatran on physician's decision before study enrolment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients should not be included if ANY ONE of the following criteria is met:&#xD;
&#xD;
          1. Contraindication to the use of dabigatran (i.e., active pathological bleeding, history&#xD;
             of a serious hypersensitivity reaction to dabigatran [e.g., anaphylactic reaction or&#xD;
             anaphylactic shock], severely impaired renal function [Creatinine clearance rate (Ccr)&#xD;
             &lt; 30 mL/min], hemorrhagic manifestations, bleeding diathesis, mechanical prosthetic&#xD;
             heart valve, congenital or acquired coagulation disorders, organic lesions with&#xD;
             bleeding tendency, or concomitantly use systemic ketoconazole, cyclosporine, and&#xD;
             itraconazole)&#xD;
&#xD;
          2. Participate in other interventional trials currently or in the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chia-Yi Christian Hospital</name>
      <address>
        <city>Chia-Yi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han Lin Tsai</last_name>
      <phone>05-2765041#7360</phone>
      <email>thl.ks@mas.hinet.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</name>
      <address>
        <city>Chia-Yi</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen-Yu Chien</last_name>
      <phone>05-2648000#5606</phone>
      <email>rightraintennis@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital-Hsin-Chu Branch</name>
      <address>
        <city>Hsinchu</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Cheng Wu</last_name>
      <phone>03-532-6151#2030</phone>
      <email>chihchengwumd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-Chin Tsai</last_name>
      <phone>03-8561825#2226</phone>
      <email>Wenchintsai38@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-I Cheng</last_name>
      <phone>+886-7-731-7123#2107</phone>
      <email>chris0921@cgmh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Municipal Da-Tung Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsung Hsien Lin</last_name>
      <phone>07-4677418</phone>
      <email>lth@kmu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Hung Chiang</last_name>
      <phone>07-342-2121#72011,72018</phone>
      <email>chenghungchiang@yahoo.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University-Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ju-Chi Liu</last_name>
      <phone>0970-746902</phone>
      <email>liumdcv@tmu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pingtung Christian Hospital</name>
      <address>
        <city>Pingtung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun-Ted Chong</last_name>
      <phone>0970679167</phone>
      <email>dr_chong@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuang-Tien General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih Chung Huang</last_name>
      <phone>+886-4-2662-5111#3305</phone>
      <email>t0935167896@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Hung Li</last_name>
      <phone>04-23592525#4043</phone>
      <email>lichcil@yahoo.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tungs' Taichung MetroHarbor Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Sheng Lin</last_name>
      <phone>04-26581919#3056</phone>
      <email>cs.lin328@msa.hinet.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Tainan,</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia-Te Liao</last_name>
      <phone>06-2812811#57332</phone>
      <email>qpig0218@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NCKUH</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting-Hsing Chao</last_name>
      <phone>88662353535#2389</phone>
      <email>chaotinghsing@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Yao Huang</last_name>
      <phone>02-27372181#8603</phone>
      <email>cyhuang@tmu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Hung Huang</last_name>
      <phone>886227082121#3116</phone>
      <email>hchbox@cgh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tien Ping Tsao</last_name>
      <phone>02-28264400#21825</phone>
      <email>9206battery@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng-Ting Tsai</last_name>
      <phone>02-25433535</phone>
      <email>chengtingtsai@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yen-Bin Liu</last_name>
      <phone>+886-2-23123456#65210</phone>
      <email>yenbinliu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Municipal Wanfang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Che Shih</last_name>
      <phone>02-2930-7930#1825</phone>
      <email>ccshih0603@tmu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tze-Fan Chao</last_name>
      <phone>02-28712121#2513</phone>
      <email>eyckeyck@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Hsiang Lin</last_name>
      <phone>02-8792-3311#16119</phone>
      <email>wslin545@ms27.hinet.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital(Linkou)</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pao-Hsien Chu</last_name>
      <phone>03-3281200#8168</phone>
      <email>pchu@cgmh.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

